Seeking Alpha

Leerink Swann calls the early success of Merck's (MRK +4.2%) odnacatib osteoporosis drug a...

Leerink Swann calls the early success of Merck's (MRK +4.2%) odnacatib osteoporosis drug a "positive upside surprise," and forecasts peak sales of $975M in 2020, and a total global sales potential of $3B+. Leerink Swann also maintains its Outperform rating on Merck's stock, while Citigroup ups its rating to "buy" from "neutral."
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs